PM&R
Volume 1, Issue 6 , Pages 547-559, June 2009

Mesenchymal Stem Cells: Emerging Therapy for Duchenne Muscular Dystrophy

  • Chad D. Markert, PhD

      Affiliations

    • Department of Neurology, School of Medicine, and Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, NC†
    • ,
  • Anthony Atala, MD

      Affiliations

    • Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, NC‡
    • ,
  • Jennifer K. Cann, BA

      Affiliations

    • Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, NC§
    • ,
  • George Christ, PhD

      Affiliations

    • Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, NC
    • ,
  • Mark Furth, PhD

      Affiliations

    • Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, NC∥
    • ,
  • Fabrisia Ambrosio, PT, PhD

      Affiliations

    • Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA#
    • ,
  • Martin K. Childers, DO, PhD

      Affiliations

    • Department of Neurology, School of Medicine, and Wake Forest University Health Sciences, Medical Center Boulevard, Winston-Salem, NC 27157-1078⁎⁎
    • Corresponding Author InformationAddress correspondence to: M.K.C.

Received 6 November 2008; accepted 25 February 2009.

Multipotent cells that can give rise to bone, cartilage, fat, connective tissue, and skeletal and cardiac muscle are termed mesenchymal stem cells. These cells were first identified in the bone marrow, distinct from blood-forming stem cells. Based on the embryologic derivation, availability, and various pro-regenerative characteristics, research exploring their use in cell therapy shows great promise for patients with degenerative muscle diseases and a number of other conditions. In this review, the authors explore the potential for mesenchymal stem cell therapy in the emerging field of regenerative medicine with a focus on treatment for Duchenne muscular dystrophy.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 
  • † Disclosure: nothing to disclose
  • ‡ Disclosure: nothing to disclose
  • § Disclosure: nothing to disclose
  •  Disclosure: nothing to disclose
  • ∥ Disclosure: nothing to disclose
  • # Disclosure: nothing to disclose
  • ⁎⁎ Disclosure: nothing to disclose

 Disclosure Key can be found on the Table of Contents and at www.pmrjournal.org

PII: S1934-1482(09)00223-8

doi:10.1016/j.pmrj.2009.02.013

PM&R
Volume 1, Issue 6 , Pages 547-559, June 2009

Article Tools

* Image Usage & Resolution